These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 10952473)

  • 41. From the Cochrane library: Ginkgo biloba for intermittent claudication.
    Nicolaï SP; Gerardu VC; Kruidenier LM; Prins MH; Teijink JA
    Vasa; 2010 May; 39(2):153-8. PubMed ID: 20464671
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Conservative management of intermittent claudication.
    Radack K; Wyderski RJ
    Ann Intern Med; 1990 Jul; 113(2):135-46. PubMed ID: 2141775
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Systematic review the efficacy and safety of cilostazol, pentoxifylline, beraprost in the treatment of intermittent claudication: A network meta-analysis.
    Liang X; Wang Y; Zhao C; Cao Y
    PLoS One; 2022; 17(11):e0275392. PubMed ID: 36318524
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Naftidrofuryl in chronic arterial disease. Results of a six month controlled multicenter study using Naftidrofuryl tablets 200 mg.
    Adhoute G; Bacourt F; Barral M; Cardon JM; Chevalier JM; Cuny A; Gillet M; Juhan C; Leguay G; Marion J
    Angiology; 1986 Mar; 37(3 Pt 1):160-7. PubMed ID: 3518547
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A comparison of cilostazol and pentoxifylline for treating intermittent claudication.
    Dawson DL; Cutler BS; Hiatt WR; Hobson RW; Martin JD; Bortey EB; Forbes WP; Strandness DE
    Am J Med; 2000 Nov; 109(7):523-30. PubMed ID: 11063952
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomized trial of iloprost in patients with intermittent claudication.
    Creager MA; Pande RL; Hiatt WR
    Vasc Med; 2008 Feb; 13(1):5-13. PubMed ID: 18372433
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical and hemorheological effects of buflomedil in diabetic subjects with intermittent claudication.
    Diamantopoulos EJ; Grigoriadou M; Ifanti G; Raptis SA
    Int Angiol; 2001 Dec; 20(4):337-44. PubMed ID: 11782701
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacological management of intermittent claudication: a meta-analysis of randomised trials.
    Moher D; Pham B; Ausejo M; Saenz A; Hood S; Barber GG
    Drugs; 2000 May; 59(5):1057-70. PubMed ID: 10852639
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [The antagonist of type-II serotonin receptors naftidrofuryl in the treatment of patients with intermittent claudication].
    Komarov AL; Panchenko EP; Eshkeeva AR; Dobrovol'skiĭ AB; Titaeva EV; Karpov IuA
    Ter Arkh; 1996; 68(2):49-53. PubMed ID: 8771659
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication.
    Bendermacher BL; Willigendael EM; Teijink JA; Prins MH
    Cochrane Database Syst Rev; 2006 Apr; (2):CD005263. PubMed ID: 16625633
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A placebo-controlled study of the effects of intravenous Buflomedil on foot skin microcirculation in patients with severe intermittent claudication.
    Van den Brande P; Maurel A
    Angiology; 1998 Feb; 49(2):105-14. PubMed ID: 9482510
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Naftidrofuryl can enhance the quality of life in patients with intermittent claudication.
    Spengel F; Brown TM; Poth J; Lehert P
    Vasa; 1999 Aug; 28(3):207-12. PubMed ID: 10483329
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacologic therapy for intermittent claudication.
    Dobesh PP; Stacy ZA; Persson EL
    Pharmacotherapy; 2009 May; 29(5):526-53. PubMed ID: 19397462
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Buflomedil in arterial occlusive disease: results of a controlled multicenter study.
    Trübestein G; Balzer K; Bisler H; Klüken N; Muller-Wiefel H; Unkel B; Mahfoud Y; Ziegler W
    Angiology; 1984 Aug; 35(8):500-5. PubMed ID: 6383127
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pentoxifylline for intermittent claudication. A critical review.
    Ernst E
    Angiology; 1994 May; 45(5):339-45. PubMed ID: 8172380
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication.
    Clyne CA; Galland RB; Fox MJ; Gustave R; Jantet GH; Jamieson CW
    Br J Surg; 1980 May; 67(5):347-8. PubMed ID: 6992909
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Naftidrofuryl in quality of life (NIQOL). A Belgian study.
    D'Hooge D; Lehert P; Clement DL
    Int Angiol; 2001 Dec; 20(4):288-94. PubMed ID: 11782694
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacological approaches to the treatment of intermittent claudication.
    Bevan EG; Waller PC; Ramsay LE
    Drugs Aging; 1992; 2(2):125-36. PubMed ID: 1596595
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The effect of naftidrofuryl (Praxilene) on intermittent claudication.
    Waters KJ; Craxford AD; Chamberlain J
    Br J Surg; 1980 May; 67(5):349-51. PubMed ID: 6992910
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Drug treatment of intermittent claudication.
    Jacoby D; Mohler ER
    Drugs; 2004; 64(15):1657-70. PubMed ID: 15257627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.